Skip to main content
Log in

The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of bupropion and 3 of its basic metabolites were determined in 8 young, healthy, male volunteers after single and multiple oral doses of bupropion. Plasma profiles were obtained: 1) after a single 100 mg oral dose of bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later. Plasma concentrations of the parent drug and metabolites were determined by high-performance liquid chromatography. Saliva secretion and pupil diameters were measured, subjective assessments of sleep made using visual analogue scales and side effects, blood counts and biochemistry were monitored. After the first dose mean elimination half lives (t1/2) of bupropion, and metabolites I and II were 8, 19 and 19 h respectively. On repeated administration there was little accumulation of the parent drug and no evidence for induction of its own metabolism. Accumulation of I was consistent with its rate of elimination after single doses while that of II was greater than predicted with prolongation of t1/2 to 35 h. Metabolite III was barely detectable after single doses but its accumulation on multiple dosing was consistent with its long half life (35 h) determined on occasion 2. Saliva secretion was significantly reduced during the multiple dosing period but there were no complaints of dry mouth. Subjective assessments of sleep were not significantly altered though one subject reported vivid dreams. There were no other adverse reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

ka :

first order rate constant for absorption or appearance

kel :

first order rate constant for elimination

F:

extent of bioavailability

D:

administered dose (as free base)

k12 :

first order distribution rate constant into peripheral compartment

k21 :

first order distribution rate constant from peripheral compartment

k10 :

first order elimination rate constant from central compartment

α:

first order elimination rate constant of rapid disposition phase

β:

first order elimination rate constant of slow disposition phase

Vz :

apparent volume of distribution

Vc :

apparent volume of distribution of central compartment

t:

time after drug administration

to :

lag time for absorption

Cp(t) :

concentration in plasma at time t

n:

number of doses

Cp(tn) :

concentration in plasma at time t after nth dose

τ:

dose interval

CL:

clearance uncorrected for bioavailability F

References

  1. Schroeder DH, Hinton ML, Smith PG, Nichol CA, Welch RM (1978) A method of analysis for bupropion and its disposition in animals and man. Fed Proc 37: 691

    Google Scholar 

  2. Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366

    Google Scholar 

  3. Park BK, Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1–24

    Google Scholar 

  4. Gelehrter TD (1976) Enzyme induction. N Engl J Med 294: 589–595

    Google Scholar 

  5. Vessell ES (1980) The value of antipyrine and aminopyrine as model substrates in assessing drug-metabolising capacity in man. TIPS 1 [16]: IV-V

    Google Scholar 

  6. Park BK (1981) Assessment of urinary 6-β-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol 12: 97–102

    Google Scholar 

  7. Hunter J, Maxwell JD, Carrella M, Steward DA, Williams R (1971) Urinary D-glucaric acid excretion as a test for hepatic enzyme induction in man. Lancet 1: 572–584

    Google Scholar 

  8. Whitfield JB, Moss DW, Neale G, Orme M, Breckenridge A (1973) Changes in plasma gamma glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J 1: 316–318

    Google Scholar 

  9. Rapeport WG, McInnes GT, Thompson GG, Forrest G, Park BK, Brodie BJ (1983) Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: Studies with carbamazepine. Br J Clin Pharmacol 16: 133–137

    Google Scholar 

  10. Gerardin AP, Abadhe FV, Campestrini JA, Theobald W (1976) Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm 4: 521–535

    Google Scholar 

  11. Nitti V, Delli V, Ninni A, Meola G (1972) Rifampicin blood serum levels and half life during prolonged administration in tuberculosis patients. Chemotherapy 17: 121–129

    Google Scholar 

  12. Nitti V, Ninni A, Meola G, Iuliano A, Curci G (1973) Comparative investigations of the enzyme-inducing activity of rifampicin and barbiturates in man. Chemotherapy 19: 206–210

    Google Scholar 

  13. Zung WWK (1983) Review of placebo controlled trials with bupropion. J Clin Psychiatry 44 (5) [Sec 2]: 104–114

    Google Scholar 

  14. Lader M (1975) The psychophysiology of mental illness. Routledge and Kegan Paul, London, p 29

    Google Scholar 

  15. Cooper TB, Suckow RF, Glassman A (1984) Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual wave length UV detection. J Pharm Sci 73: 1104–1107

    Google Scholar 

  16. Sedman AJ, Wagner JG (1974) CSTRIP a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65: 1006

    Google Scholar 

  17. Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modelling. Biometrics 30: 362

    Google Scholar 

  18. Findlay JWA, Fleet JVW, Smith PG, Butz RF, Hinton ML, Blum MR, Schroeder DH (1981) Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Europ J Clin Pharmacol 21: 127–135

    Google Scholar 

  19. Becker RE, Dufresne RL (1982) Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 139: 1200–1201

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Posner, J., Bye, A., Dean, K. et al. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol 29, 97–103 (1985). https://doi.org/10.1007/BF00547376

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00547376

Key words

Navigation